Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

Sales of Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy continue to soar, surpassing Wall Street expectations. The ...

Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

Novo Nordisk reported forecast-beating quarterly sales of its popular Wegovy weight-loss drug on Wednesday, sending its ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...

Novo Nordisk A/S shares rose as surging sales of the blockbuster weight-loss treatment Wegovy reassured investors after rival ...

Novo Nordisk’s net profit of $3.94bn represents a 21% increase from Q3 2023. Net sales in the quarter jumped by the same ...

Novo Nordisk is stealing the spotlight in the obesity drug market as Wegovy's sales skyrocketed by 76% year-over-year to DKK ...

Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its ...

Novo Nordisk's (NVO) semaglutide, marketed as Wegovy for obesity, shows promise in reducing joint disease symptoms in ...